

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin / Pyrantel Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : No. 485 Jing Tai Road  
Pu Tuo District - Shanghai - China 200331

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

### 2. HAZARDS IDENTIFICATION

#### Emergency Overview

|            |                     |
|------------|---------------------|
| Appearance | : powder            |
| Colour     | : brown             |
| Odour      | : No data available |

Very toxic to aquatic life with long lasting effects.

#### GHS Classification

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

#### GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H410 Very toxic to aquatic life with long lasting effects.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

**Precautionary statements :**

**Prevention:**  
P273 Avoid release to the environment.

**Response:**  
P391 Collect spillage.

**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

### Physical and chemical hazards

Not classified based on available information.

### Health hazards

Not classified based on available information.

### Environmental hazards

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

### Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 8.6 %

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

| Chemical name   | CAS-No.    | Concentration (% w/w)  |
|---|------------|------------------------|
| 4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1) | 22204-24-6 | $\geq 1$ -< 10         |
| Sodium chloride   | 7647-14-5  | $\geq 1$ -< 10         |
| Ivermectin  | 70288-86-7 | $\geq 0.0025$ -< 0.025 |

## 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

|   |   |   |
|---|---|---|
| In case of eye contact                                      | : | If in eyes, rinse well with water.<br>Get medical attention if irritation develops and persists.  |
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.<br>Rinse mouth thoroughly with water.                   |
| Most important symptoms and effects, both acute and delayed | : | Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation. |
| Protection of first-aiders                                  | : | No special precautions are necessary for first aid responders.  |
| Notes to physician  | : | Treat symptomatically and supportively.   |

### 5. FIREFIGHTING MEASURES

|   |   |   |
|---|---|---|
| Suitable extinguishing media                  | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                | : | None known.   |
| Specific hazards during fire-fighting         | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health.                   |
| Hazardous combustion products                 | : | Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )<br>Sulphur oxides<br>Metal oxides<br>Chlorine compounds   |
| Specific extinguishing methods                | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for firefighters | : | Wear self-contained breathing apparatus for firefighting if necessary.<br>Use personal protective equipment.  |

### 6. ACCIDENTAL RELEASE MEASURES

|   |   |  |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions   | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.                     |

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

### Handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

### Storage

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

Version 5.0      Revision Date: 2025/04/14      SDS Number: 52640-00032      Date of last issue: 2024/09/28  
Date of first issue: 2015/02/02

| Components  | CAS-No.    | Value type<br>(Form of exposure) | Control parameters / Permissible concentration | Basis    |
|---|------------|----------------------------------|--|----------|
| 4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1) | 22204-24-6 | TWA                              | 250 µg/m3 (OEB 2)                              | Internal |
| Ivermectin  | 70288-86-7 | TWA                              | 30 µg/m3 (OEB 3)                               | Internal |
| Further information: Skin   |            | Wipe limit                       | 300 µg/100 cm2                                 | Internal |

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type  
**Eye/face protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.  
**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures,

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

|  |   |   |
|--|---|---|
| Appearance                                       | : | powder  |
| Colour   | : | brown   |
| Odour  | : | No data available   |
| Odour Threshold                                  | : | No data available   |
| pH   | : | 4 - 6 (20 °C)<br>(as aqueous solution)  |
| Melting point/freezing point                     | : | No data available   |
| Initial boiling point and boiling range          | : | No data available   |
| Flash point                                      | : | Not applicable  |
| Evaporation rate                                 | : | Not applicable  |
| Flammability (solid, gas)                        | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : | Not applicable  |
| Upper explosion limit / Upper flammability limit | : | No data available   |
| Lower explosion limit / Lower flammability limit | : | No data available   |
| Vapour pressure                                  | : | Not applicable  |
| Relative vapour density                          | : | Not applicable  |
| Relative density                                 | : | No data available   |
| Density  | : | No data available   |
| Solubility(ies)<br>Water solubility              | : | No data available   |
| Partition coefficient: n-octanol/water           | : | Not applicable  |
| Auto-ignition temperature                        | : | No data available   |
| Decomposition temperature                        | : | No data available   |

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

|                          |   |  |
|--------------------------|---|--|
| Viscosity                |   |  |
| Viscosity, kinematic     | : | Not applicable   |
| Explosive properties     | : | Not explosive  |
| Oxidizing properties     | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight         | : | No data available  |
| Particle characteristics |   |  |
| Particle size            | : | No data available  |

### 10. STABILITY AND REACTIVITY

|                                    |   |  |
|------------------------------------|---|--|
| Reactivity                         | : | Not classified as a reactivity hazard.   |
| Chemical stability                 | : | Stable under normal conditions.  |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means.<br>Can react with strong oxidizing agents. |
| Conditions to avoid                | : | Heat, flames and sparks.<br>Avoid dust formation.  |
| Incompatible materials             | : | Oxidizing agents   |
| Hazardous decomposition products   | : | No hazardous decomposition products are known.   |

### 11. TOXICOLOGICAL INFORMATION

|                 |   |  |
|-----------------|---|--|
| Exposure routes | : | Inhalation<br>Skin contact<br>Ingestion<br>Eye contact |
|-----------------|---|--|

#### Acute toxicity

Not classified based on available information.

#### Product:

|                     |   |  |
|---------------------|---|--|
| Acute oral toxicity | : | Acute toxicity estimate: > 5,000 mg/kg<br>Method: Calculation method |
|---------------------|---|--|

#### Components:

**4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

|                     |   |  |
|---------------------|---|--|
| Acute oral toxicity | : | LD50 (Rat): > 24,000 mg/kg<br>LD50 (Mouse): > 24,000 mg/kg |
|---------------------|---|--|

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

LD50 (Dog): 2,000 mg/kg

### Sodium chloride:

|                           |   |
|---------------------------|---|
| Acute oral toxicity       | : LD50 (Rat): 3,550 mg/kg   |
| Acute inhalation toxicity | : LC50 (Rat): > 42 mg/l<br>Exposure time: 1 h<br>Test atmosphere: dust/mist |
| Acute dermal toxicity     | : LD50 (Rabbit): > 5,000 mg/kg  |

### Ivermectin:

|                           |   |
|---------------------------|---|
| Acute oral toxicity       | : LD50 (Rat): 50 mg/kg<br>LD50 (Mouse): 25 mg/kg<br>LD50 (Monkey): > 24 mg/kg<br>Target Organs: Central nervous system<br>Symptoms: Vomiting, Dilatation of the pupil<br>Remarks: No mortality observed at this dose. |
| Acute inhalation toxicity | : LC50 (Rat): 5.11 mg/l<br>Exposure time: 1 h<br>Test atmosphere: dust/mist   |
| Acute dermal toxicity     | : LD50 (Rabbit): 406 mg/kg<br>LD50 (Rat): > 660 mg/kg   |

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Sodium chloride:

|         |                      |
|---------|----------------------|
| Species | : Rabbit             |
| Result  | : No skin irritation |

#### Ivermectin:

|         |                      |
|---------|----------------------|
| Species | : Rabbit             |
| Result  | : No skin irritation |

### Serious eye damage/eye irritation

Not classified based on available information.



# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

### Components:

#### **Sodium chloride:**

|         |                     |
|---------|---------------------|
| Species | : Rabbit            |
| Result  | : No eye irritation |

#### **Ivermectin:**

|         |                       |
|---------|-----------------------|
| Species | : Rabbit              |
| Result  | : Mild eye irritation |

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Sodium chloride:**

|                 |                                 |
|-----------------|---------------------------------|
| Test Type       | : Local lymph node assay (LLNA) |
| Exposure routes | : Skin contact                  |
| Species         | : Mouse                         |
| Result          | : negative                      |

#### **Ivermectin:**

|                 |                                      |
|-----------------|--------------------------------------|
| Exposure routes | : Dermal                             |
| Species         | : Humans                             |
| Result          | : Does not cause skin sensitisation. |

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

|                       |  |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative |
|-----------------------|--|

#### **Sodium chloride:**

|                       |   |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: In vitro mammalian cell gene mutation test<br>Result: positive |
|-----------------------|---|

|  |  |
|--|--|
|  | Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative |
|--|--|

|  |  |
|--|--|
|  | Test Type: Saccharomyces cerevisiae, gene mutation assay |
|--|--|

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

|                                     |  |
|-------------------------------------|--|
|                                     | (in vitro)<br>Result: positive   |
|                                     | Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)<br>Result: positive  |
|                                     | Test Type: Chromosome aberration test in vitro<br>Result: positive   |
|                                     | Test Type: Chromosome aberration test in vitro<br>Result: negative   |
| Genotoxicity in vivo                | : Test Type: In vivo micronucleus test<br>Species: Mouse<br>Application Route: Intraperitoneal injection<br>Result: negative   |
|                                     | Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)<br>Species: Rat<br>Application Route: Intraperitoneal injection<br>Result: positive |
| Germ cell mutagenicity - Assessment | : Weight of evidence does not support classification as a germ cell mutagen.   |

### Ivermectin:

|                       |   |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative  |
|                       | Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)<br>Test system: human diploid fibroblasts<br>Result: negative |
|                       | Test Type: Mouse Lymphoma<br>Result: negative   |

### Carcinogenicity

Not classified based on available information.

### Components:

#### Sodium chloride:

|                   |             |
|-------------------|-------------|
| Species           | : Rat       |
| Application Route | : Ingestion |
| Exposure time     | : 2 Years   |
| Result            | : negative  |

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

### Ivermectin:

|                   |  |
|-------------------|--|
| Species           | : Rat                                  |
| Application Route | : Oral                                 |
| NOAEL             | : 1.5 mg/kg body weight                |
| Result            | : negative                             |
| Remarks           | : Based on data from similar materials |

|                   |  |
|-------------------|--|
| Species           | : Mouse                                |
| Application Route | : Oral                                 |
| NOAEL             | : 2.0 mg/kg body weight                |
| Result            | : negative                             |
| Remarks           | : Based on data from similar materials |

### Reproductive toxicity

Not classified based on available information.

### Components:

#### 4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

|                               |   |
|-------------------------------|---|
| Effects on foetal development | : Test Type: Embryo-foetal development<br>Species: Rat<br>Application Route: Oral<br>Developmental Toxicity: NOAEL: 3,000 mg/kg body weight<br>Result: No effects on fertility and early embryonic development were detected. |
|-------------------------------|---|

|  |  |
|--|--|
|  | : Test Type: Embryo-foetal development<br>Species: Rabbit<br>Application Route: Oral<br>Developmental Toxicity: NOAEL: 1,000 mg/kg body weight<br>Result: No effects on fertility and early embryonic development were detected. |
|--|--|

### Ivermectin:

|                      |   |
|----------------------|---|
| Effects on fertility | : Test Type: Fertility<br>Species: Rat<br>Application Route: Oral<br>Fertility: NOAEL: 0.6 mg/kg body weight<br>Result: Animal testing did not show any effects on fertility. |
|----------------------|---|

|                               |  |
|-------------------------------|--|
| Effects on foetal development | : Test Type: Development<br>Species: Mouse<br>Application Route: Oral<br>Developmental Toxicity: NOAEL: 0.2 mg/kg body weight<br>Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses |
|-------------------------------|--|

|  |                          |
|--|--------------------------|
|  | : Test Type: Development |
|--|--------------------------|

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected.  
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

### STOT - single exposure

Not classified based on available information.

#### Components:

##### Ivermectin:

|               |                            |
|---------------|----------------------------|
| Target Organs | : Central nervous system   |
| Assessment    | : Causes damage to organs. |

### STOT - repeated exposure

Not classified based on available information.

#### Components:

##### Ivermectin:

|               |   |
|---------------|---|
| Target Organs | : Central nervous system  |
| Assessment    | : Causes damage to organs through prolonged or repeated exposure. |

### Repeated dose toxicity

#### Components:

**4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

|                   |  |
|-------------------|--|
| Species           | : Dog  |
| NOAEL             | : 10 mg/kg                                     |
| LOAEL             | : 30 mg/kg                                     |
| Application Route | : Ingestion                                    |
| Exposure time     | : 3 d  |
| Remarks           | : No significant adverse effects were reported |

|                   |             |
|-------------------|-------------|
| Species           | : Dog       |
| NOAEL             | : 600 mg/kg |
| Application Route | : Oral      |

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

|               |  |
|---------------|--|
| Exposure time | : 19 d   |
| Remarks       | : No significant adverse effects were reported |

|                   |  |
|-------------------|--|
| Species           | : Dog  |
| NOAEL             | : 600 mg/kg                                    |
| Application Route | : Oral   |
| Exposure time     | : 30 d   |
| Remarks           | : No significant adverse effects were reported |

|                   |  |
|-------------------|--|
| Species           | : Dog  |
| NOAEL             | : 600 mg/kg                                    |
| Application Route | : Oral   |
| Exposure time     | : 90 d   |
| Remarks           | : No significant adverse effects were reported |

### Sodium chloride:

|                   |               |
|-------------------|---------------|
| Species           | : Rat         |
| LOAEL             | : 2,533 mg/kg |
| Application Route | : Ingestion   |
| Exposure time     | : 2 yr        |

### Ivermectin:

|                   |  |
|-------------------|--|
| Species           | : Dog  |
| NOAEL             | : 0.5 mg/kg  |
| LOAEL             | : 1 mg/kg  |
| Application Route | : Oral   |
| Exposure time     | : 14 Weeks   |
| Target Organs     | : Central nervous system   |
| Symptoms          | : Dilatation of the pupil, Tremors, Lack of coordination, anorexia |

|                   |  |
|-------------------|--|
| Species           | : Monkey                                       |
| NOAEL             | : 1.2 mg/kg                                    |
| Application Route | : Oral   |
| Exposure time     | : 2 Weeks                                      |
| Remarks           | : No significant adverse effects were reported |

|                   |                               |
|-------------------|-------------------------------|
| Species           | : Rat                         |
| NOAEL             | : 0.4 mg/kg                   |
| LOAEL             | : 0.8 mg/kg                   |
| Application Route | : Oral                        |
| Exposure time     | : 3 Months                    |
| Target Organs     | : spleen, Bone marrow, Kidney |

### Aspiration toxicity

Not classified based on available information.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

### Experience with human exposure

#### Components:

**4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Fever

#### **Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

**4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

#### **Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

#### **Sodium chloride:**

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 4,136 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50: > 2,000 mg/l  
Exposure time: 96 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 252 mg/l  
Exposure time: 33 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia pulex (Water flea)): 314 mg/l  
Exposure time: 21 d

Toxicity to microorganisms : EC10: > 1,000 mg/l

#### **Ivermectin:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l  
Exposure time: 96 h

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

|   |  |
|---|--|
|   | LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l<br>Exposure time: 96 h  |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l<br>Exposure time: 48 h  |
| Toxicity to algae/aquatic plants                    | : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201 |
|   | NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201     |
| M-Factor (Acute aquatic toxicity)                   | : 10,000   |
| M-Factor (Chronic aquatic toxicity)                 | : 10,000   |

### Persistence and degradability

#### Components:

##### Ivermectin:

|                  |  |
|------------------|--|
| Biodegradability | : Result: Not readily biodegradable.<br>Biodegradation: 50 %<br>Exposure time: 240 d |
|------------------|--|

### Bioaccumulative potential

#### Components:

##### Ivermectin:

|  |                                     |
|--|-------------------------------------|
| Bioaccumulation                        | : Bioconcentration factor (BCF): 74 |
| Partition coefficient: n-octanol/water | : log Pow: 3.22                     |

### Mobility in soil

No data available

### Other adverse effects

No data available

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

|                     |   |
|---------------------|---|
| Waste from residues | : Do not dispose of waste into sewer.<br>Dispose of in accordance with local regulations. |
|---------------------|---|

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ivermectin)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

##### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Ivermectin)  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

##### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ivermectin)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### National Regulations

##### GB 6944/12268

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(Ivermectin)  
Class : 9



# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

Packing group : III  
Labels : 9  
Marine pollutant : no

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 15. REGULATORY INFORMATION

### National regulatory information

#### Law on the Prevention and Control of Occupational Diseases

#### Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the catalogue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of determination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218) : Not listed

Hazardous Chemicals for Priority Management under SAWS : Not listed

Catalogue of Specially Controlled Hazardous Chemicals : Not listed

List of Explosive Precursors : Not listed

### Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

### Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export : Not listed

### Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

### Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

### Regulations of Ozone Depleting Substances Management

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

|   |              |
|---|--------------|
| List of Controlled Ozone Depleting Substances Import and Export | : Not listed |
| List of Controlled Ozone Depleting Substances                   | : Not listed |

### Environmental Protection Law

|                                       |              |
|---------------------------------------|--------------|
| List of Priority Controlled Chemicals | : Not listed |
| List of Key Controlled New Pollutants | : Not listed |

### The components of this product are reported in the following inventories:

|       |                  |
|-------|------------------|
| AICS  | : not determined |
| DSL   | : not determined |
| IECSC | : not determined |

## 16. OTHER INFORMATION

Revision Date : 2025/04/14

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships;

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Ivermectin / Pyrantel Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28  |
| 5.0     | 2025/04/14     | 52640-00032 | Date of first issue: 2015/02/02 |

---

n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN